US4364401012 - Common Stock
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Based on the average brokerage recommendation (ABR), Hologic (HOLX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Based on the average brokerage recommendation (ABR), Hologic (HOLX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Here is how High Tide Inc. (HITI) and Hologic (HOLX) have performed compared to their sector so far this year.
Review Hologic's (HOLX) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
HOLX stock results show that Hologic beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Hologic (NASDAQ:HOLX) just reported results for the second quarter of 2024.Holo...
Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) reachead $75.36 at the closing of the latest trading day, reflecting a -0.03% change compared to its last close.
Illumina chairman and Hologic CEO Stephen MacMillan is no stranger to dealing with well-known activist investors.
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
/PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases,...
Hologic (HOLX) reachead $76.08 at the closing of the latest trading day, reflecting a -0.05% change compared to its last close.
Hologic (HOLX) closed at $75.65 in the latest trading session, marking a +0.52% move from the prior day.